{
    "eid": "2-s2.0-85164490433",
    "title": "Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Health Policy",
            "@code": "2719",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Budget impact analysis",
        "chronic hepatitis b",
        "economic evaluation",
        "hepatocellular carcinoma",
        "risk prediction algorithms"
    ],
    "authors": [
        "Piyameth Dilokthornsakul",
        "Ratree Sawangjit",
        "Pisit Tangkijvanich",
        "Maneerat Chayanupatkul",
        "Pajaree Sriuttha",
        "Unchalee Permsuwan"
    ],
    "citedby-count": 0,
    "ref-count": 42,
    "ref-list": [
        "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015",
        "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study",
        "Access to treatment for hepatitis B virus infection - worldwide, 2016",
        "Update on prevention, diagnosis, and treatment of chronic hepatitis B: aASLD 2018 hepatitis B guidance",
        "Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection",
        "Thailand practice guideline for management of chronic hepatitis B and C 2015",
        "Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada",
        "The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy",
        "Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis",
        "Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis",
        "Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B",
        "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B",
        "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers",
        "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score",
        "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy",
        "Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa",
        "Assessment and validation of the TREAT-B score to assess the treatment eligibility of patients with chronic hepatitis B virus infection",
        "Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial",
        "Economic evaluation of oral nucleos(t)ide analogues for patients with chronic hepatitis B in Thailand",
        "Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study",
        "A novel and simplified score for determining treatment eligibility for patients with chronic hepatitis B",
        "Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors",
        "Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area",
        "Weight reduction and pioglitazone are cost-effective for the treatment of non-alcoholic fatty liver disease in Thailand",
        "Health-related quality of life as measured by EQ-5D and TFLIC-2 in liver cancer patients",
        "The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons",
        "Standard cost list for health technology assessment (in Thai language)",
        "Economic evaluation and budget impact analysis of liver transplantation among Thai adults in universal health insurance coverage in Thailand",
        "Resource utilization and direct medical costs of chronic hepatitis C in Thailand: a heavy but manageable economic burden",
        "Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients",
        "Drug and medical supply information center: ministry of public health. median price for medications",
        "Consumer price index",
        "Handling time in economic evaluation studies",
        "Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis",
        "Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review",
        "Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Maha Sarakham",
            "@id": "60002875",
            "affilname": "Mahasarakham University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002875",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "GSK"
    ]
}